AFIB RSI Chart
Last 7 days
50%
Last 30 days
-62.5%
Last 90 days
-70%
Trailing 12 Months
-93.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 4.1M | 5.1M | 6.1M | 7.2M |
2022 | 17.4M | 16.7M | 15.8M | 3.0M |
2021 | 10.5M | 14.0M | 15.5M | 17.3M |
2020 | 4.2M | 5.7M | 7.1M | 8.5M |
2019 | 0 | 0 | 0 | 2.8M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 01, 2024 | mukai takeo | sold (taxes) | -1,779 | 0.21 | -8,475 | cfo |
Feb 06, 2024 | sohn tom | sold (taxes) | -1,311 | 0.173 | -7,582 | svp, gen. counsel & secretary |
Feb 01, 2024 | sohn tom | sold (taxes) | -1,090 | 0.191 | -5,709 | svp, gen. counsel & secretary |
Feb 01, 2024 | mukai takeo | sold (taxes) | -547 | 0.191 | -2,869 | cfo |
Jan 07, 2024 | mathews kevin | sold (taxes) | -1,198 | 0.189 | -6,342 | svp, commercial |
Jan 07, 2024 | roman david | sold (taxes) | -4,552 | 0.189 | -24,086 | president & ceo |
Sep 01, 2023 | mukai takeo | sold (taxes) | -843 | 0.488 | -1,729 | cfo |
Aug 05, 2023 | sohn tom | sold (taxes) | -298 | 0.69 | -433 | svp, gen. counsel & secretary |
Aug 05, 2023 | mathews kevin | sold (taxes) | -92.46 | 0.69 | -134 | svp, commercial |
Aug 02, 2023 | mukai takeo | sold (taxes) | - | - | -501 | cfo |
Which funds bought or sold AFIB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | unchanged | - | -721 | 9,752 | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | sold off | -100 | -2,300 | - | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -32.8 | - | - | -% |
May 15, 2024 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | unchanged | - | -36,985 | 500,232 | 0.01% |
May 15, 2024 | ORBIMED ADVISORS LLC | unchanged | - | -36,812 | 497,897 | 0.01% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | sold off | -100 | -22,947 | - | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | new | - | 14,759 | 14,759 | -% |
May 15, 2024 | First Business Financial Services, Inc. | sold off | -100 | -2,019 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 0.89 | -145 | 2,231 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -37.58 | -66.00 | 94.00 | -% |
Unveiling Acutus Medical, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Acutus Medical, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 181.0B | 40.3B | 32.18 | 4.49 | ||||
BDX | 68.3B | 19.7B | 51.24 | 3.46 | ||||
ALGN | 20.4B | 3.9B | 44.2 | 5.22 | ||||
BAX | 18.0B | 14.9B | 6.79 | 1.21 | ||||
MID-CAP | ||||||||
ATR | 9.8B | 3.5B | 31.27 | 2.76 | ||||
HSIC | 9.6B | 12.5B | 24.63 | 0.77 | ||||
BIO | 8.4B | 2.6B | -26.02 | 3.22 | ||||
XRAY | 5.9B | 3.9B | -62.84 | 1.49 | ||||
AXNX | 3.4B | 387.1M | -216.3 | 8.9 | ||||
PDCO | 2.3B | 6.6B | 11.93 | 0.35 | ||||
SMALL-CAP | ||||||||
AHCO | 1.3B | 3.2B | -1.91 | 0.41 | ||||
ANIK | 376.6M | 169.3M | -4.9 | 2.23 | ||||
ANGO | 241.9M | 324.0M | -1.26 | 0.75 | ||||
APYX | 56.1M | 50.5M | -2.46 | 1.11 | ||||
AEMD | 1.0M | 3.7M | -0.09 | 0.28 |
Acutus Medical, Inc. News
Income Statement (Quarterly) | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 |
Revenue | -18.2% | 3,625,000 | 4,431,500 | 5,238,000 | 5,289,000 | 4,170,000 | 3,907,000 | 3,644,000 | 4,076,000 | 3,681,000 | 4,362,000 | 4,601,000 | 4,709,000 | 3,591,000 | 2,574,000 | 3,173,000 | 1,134,000 | 1,583,000 | 1,114,500 | 646,000 | 734,000 |
Gross Profit | -100.5% | -30,000 | 5,614,000 | -3,357,000 | -2,774,000 | -2,620,000 | 10,278,000 | -3,307,000 | -5,621,000 | -3,260,000 | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses | 101.8% | 545,000 | -30,072,000 | 9,579,000 | 14,397,000 | 14,687,000 | -74,928,000 | 17,154,000 | -20,549,000 | 35,370,000 | 34,262,000 | 31,690,000 | 32,009,000 | 31,424,000 | 30,580,000 | 29,435,000 | 20,599,000 | 19,183,000 | - | 31,810,000 | 14,609,000 |
S&GA Expenses | 127.3% | 3,337,000 | -12,214,500 | 7,432,000 | 9,284,000 | 9,565,000 | -17,892,000 | 9,679,000 | 14,143,000 | 14,385,000 | 15,865,000 | 15,805,000 | 15,601,000 | 16,252,000 | 15,164,000 | 15,833,000 | 9,125,000 | 10,235,000 | - | 7,978,000 | 6,927,000 |
R&D Expenses | 100.0% | - | -14,229,500 | 4,795,000 | 6,799,000 | 6,117,000 | -18,766,000 | 5,946,000 | 7,935,000 | 8,003,000 | 8,840,000 | 9,299,000 | 9,174,000 | 9,370,000 | 8,962,000 | 8,343,000 | 8,176,000 | 7,973,000 | 7,540,000 | 5,865,000 | 5,247,000 |
EBITDA Margin | 240.1% | 1.18 | -0.84 | 6.58 | 6.53 | 14.19 | 11.34 | -4.73 | -4.92 | -6.72 | -6.15 | -6.78 | -7.72 | -9.92 | - | - | - | - | - | - | - |
Interest Expenses | -4.3% | 1,478,000 | 1,544,500 | 1,409,000 | 1,395,000 | 1,307,000 | 1,339,000 | 1,109,000 | 1,290,000 | 1,411,000 | 1,415,000 | 1,441,000 | 1,456,000 | 1,388,000 | 1,416,000 | 1,366,000 | 1,370,000 | 1,354,000 | - | 1,394,000 | 13,769,000 |
Income Taxes | 100.0% | - | -12,000 | 75,000 | - | - | 15,000 | - | - | - | - | - | - | - | 23,000 | - | - | - | - | - | - |
Earnings Before Taxes | -105.7% | -2,055,000 | 35,965,000 | -13,162,000 | -18,346,000 | -16,315,000 | 83,572,000 | -20,425,000 | 5,718,000 | -40,017,000 | -31,264,000 | -28,511,000 | -28,727,000 | -29,181,000 | -29,379,000 | -31,288,000 | -23,193,000 | -18,098,000 | - | - | - |
EBT Margin | 120.3% | 0.34 | -1.66 | 5.83 | 5.59 | 12.93 | 9.52 | -5.46 | -5.63 | -7.41 | -6.82 | -7.48 | -8.44 | -10.79 | - | - | - | - | - | - | - |
Net Income | 95.2% | -1,620,000 | -33,765,000 | -13,237,000 | -18,346,000 | -16,315,000 | 15,108,000 | -20,425,000 | 5,718,000 | -40,017,000 | -31,264,000 | -28,511,000 | -28,727,000 | -29,181,000 | -29,421,000 | -31,288,000 | -23,193,000 | -18,098,000 | - | -32,085,000 | -30,345,000 |
Net Income Margin | 18.0% | -9.35 | -11.40 | -5.35 | -7.84 | -3.92 | -13.07 | -5.46 | -5.63 | -7.41 | -6.82 | -7.49 | -8.44 | -10.80 | - | - | - | - | - | - | - |
Free Cashflow | -1.2% | -17,034,000 | -16,838,000 | -14,418,000 | -15,334,000 | -16,747,000 | -14,619,000 | -22,108,000 | -23,730,000 | -28,688,000 | -25,968,000 | -27,946,000 | -25,775,000 | -29,966,000 | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
Assets | -22.8% | 42.00 | 54.00 | 85.00 | 100 | 116 | 133 | 115 | 138 | 132 | 170 | 197 | 141 | 162 | 193 | 213 | 72.00 | 105 |
Current Assets | -25.6% | 34.00 | 46.00 | 73.00 | 87.00 | 102 | 118 | 94.00 | 116 | 104 | 126 | 156 | 102 | 116 | 151 | 176 | 46.00 | 82.00 |
Cash Equivalents | -3.7% | 18.00 | 19.00 | 24.00 | 23.00 | 23.00 | 26.00 | 32.00 | 51.00 | 12.00 | 24.00 | 59.00 | 7.00 | 9.00 | 25.00 | 58.00 | 24.00 | 10.00 |
Inventory | 37.6% | 6.00 | 4.00 | 16.00 | 16.00 | 15.00 | 2.00 | 15.00 | 15.00 | 18.00 | 16.00 | 15.00 | 15.00 | 14.00 | 13.00 | 11.00 | 12.00 | 8.00 |
Net PPE | 2.3% | 1.00 | 1.00 | 7.00 | 7.00 | 8.00 | 2.00 | 10.00 | 11.00 | 13.00 | 14.00 | 15.00 | 15.00 | 15.00 | 12.00 | 10.00 | 8.00 | 4.00 |
Goodwill | - | - | - | - | - | - | - | - | - | - | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 |
Liabilities | -16.7% | 46.00 | 55.00 | 53.00 | 57.00 | 56.00 | 58.00 | 57.00 | 62.00 | 63.00 | 64.00 | 64.00 | 65.00 | 62.00 | 66.00 | 60.00 | 75.00 | 78.00 |
Current Liabilities | -47.9% | 10.00 | 19.00 | 15.00 | 18.00 | 17.00 | 20.00 | 18.00 | 23.00 | 17.00 | 19.00 | 18.00 | 18.00 | 18.00 | 22.00 | 16.00 | 31.00 | 32.00 |
Long Term Debt | 0.5% | 33.00 | 33.00 | 35.00 | 35.00 | 35.00 | 34.00 | 34.00 | 34.00 | 41.00 | 40.00 | 40.00 | 40.00 | 39.00 | 39.00 | 39.00 | 39.00 | 38.00 |
LT Debt, Current | -2.4% | 2.00 | 2.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 33.00 | 35.00 | 35.00 | 35.00 | 34.00 | 34.00 | 34.00 | 41.00 | 40.00 | 40.00 | 40.00 | 39.00 | 39.00 | 39.00 | 39.00 | 38.00 |
Shareholder's Equity | -357.3% | -4.02 | -0.88 | 32.00 | 44.00 | 60.00 | 75.00 | 58.00 | 77.00 | 69.00 | 106 | 134 | 76.00 | 100 | 127 | 153 | - | - |
Retained Earnings | -0.3% | -601 | -599 | -566 | -552 | -534 | -518 | -533 | -513 | -518 | -478 | -447 | -418 | -390 | -361 | -331 | -300 | -259 |
Additional Paid-In Capital | -0.3% | 598 | 600 | 599 | 598 | 596 | 594 | 592 | 590 | 588 | 585 | 581 | 495 | 490 | 487 | 484 | 36.00 | 33.00 |
Shares Outstanding | 1.4% | 30.00 | 29.00 | 29.00 | 29.00 | 29.00 | 29.00 | 28.00 | 28.00 | 28.00 | 28.00 | 29.00 | 28.00 | 28.00 | - | - | - | - |
Float | - | - | - | - | 26.00 | - | - | - | 32.00 | - | - | - | 304 | - | - | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 |
Cashflow From Operations | 6.0% | -16,929 | -18,013 | -14,008 | -14,582 | -16,515 | -16,864 | -21,353 | -23,100 | -27,600 | -22,582 | -27,200 | -23,627 | -26,273 | -24,162 | -26,277 | -17,203 | -17,558 | - | - | - |
Share Based Compensation | 110.7% | 202 | -1,883 | 1,278 | 1,734 | 1,904 | -4,097 | 1,884 | 2,581 | 3,032 | 3,491 | 3,577 | 3,776 | 2,910 | 2,831 | 6,374 | 1,157 | 1,741 | - | 812 | 803 |
Cashflow From Investing | -17.7% | 9,230 | 11,220 | 16,949 | 15,137 | 15,249 | 12,218 | 3,365 | 73,169 | 15,999 | -11,424 | -3,532 | 21,850 | 12,172 | -9,569 | -106,905 | 20,933 | 31,717 | - | - | - |
Cashflow From Financing | 91.5% | -42.00 | -495 | -1,935 | -21.00 | -213 | 485 | -458 | -11,601 | -42.00 | -514 | 82,232 | 229 | -2,378 | 433 | 167,115 | -531 | -2,584 | - | - | - |
Buy Backs | 100.0% | - | -275 | 12.00 | 46.00 | 217 | 49.00 | 17.00 | 45.00 | - | - | - | - | - | - | - | - | - | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Statement of Comprehensive Income [Abstract] | ||
Revenue | $ 3,625 | $ 1,242 |
Cost of products sold | 3,655 | 2,111 |
Gross loss | (30) | (869) |
Operating (income) expenses: | ||
Research and development | 0 | 938 |
Selling, general and administrative | 3,337 | 4,472 |
Change in fair value of contingent consideration | 0 | 200 |
Gain on sale of business | (2,792) | (1,207) |
Total operating expenses | 545 | 4,403 |
Loss from operations | (575) | (5,272) |
Other income (expense): | ||
Change in fair value of warrant liability | (283) | 1,446 |
Interest income | 281 | 853 |
Interest expense | (1,478) | (1,307) |
Total other (expense) income, net | (1,480) | 992 |
Loss from continuing operations before income taxes | (2,055) | (4,280) |
Income tax expense | 0 | 0 |
Net loss from continuing operations | (2,055) | (4,280) |
Discontinued operations: | ||
Income (loss) from discontinued operations before taxes | 445 | (12,035) |
Income tax expense - discontinued operations | (10) | 0 |
Income (loss) from discontinued operations | 435 | (12,035) |
Net loss | (1,620) | (16,315) |
Other comprehensive income (loss) | ||
Unrealized gain on marketable securities | 0 | 12 |
Foreign currency translation adjustment | 0 | 59 |
Comprehensive loss | $ (1,620) | $ (16,244) |
Net (loss) earnings per share, basic and diluted | ||
Net loss- continuing operations, basic (in dollars per share) | $ (0.07) | $ (0.15) |
Net loss- continuing operations, diluted (in dollars per share) | (0.07) | (0.15) |
Net income (loss)- discontinued operations, basic (in dollars per share) | 0.01 | (0.42) |
Net income (loss)- discontinued operations, diluted (in dollars per share) | 0.01 | (0.42) |
Net loss per common share, basic (in dollars per share) | (0.06) | (0.57) |
Net loss per common share, diluted (in dollars per share) | $ (0.06) | $ (0.57) |
Weighted Average Number of Shares Outstanding Reconciliation [Abstract] | ||
Weighted average number of common shares outstanding, basic (in shares) | 29,693,926 | 28,764,444 |
Weighted average number of common shares outstanding, diluted (in shares) | 29,693,926 | 28,764,444 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 18,459 | $ 19,170 |
Marketable securities, short-term | 1,495 | 3,233 |
Restricted cash, short-term | 0 | 7,030 |
Accounts receivable | 7,750 | 11,353 |
Inventory | 5,888 | 4,278 |
Prepaid expenses and other current assets | 572 | 678 |
Current assets of discontinued operations | 240 | 510 |
Total current assets | 34,404 | 46,252 |
Noncurrent assets | ||
Property and equipment, net | 844 | 825 |
Right-of-use assets, net | 3,011 | 3,189 |
Other assets | 94 | 94 |
Noncurrent assets of discontinued operations | 3,315 | 3,600 |
Total assets | 41,668 | 53,960 |
Current liabilities: | ||
Accounts payable | 3,165 | 2,761 |
Accrued liabilities | 2,063 | 2,887 |
Operating lease liabilities, short-term | 835 | 718 |
Long-term debt, current portion | 1,819 | 1,864 |
Warrant liability | 692 | 409 |
Current liabilities of discontinued operations | 1,300 | 10,303 |
Total current liabilities | 9,874 | 18,942 |
Operating lease liabilities, long-term | 3,009 | 3,243 |
Long-term debt | 32,805 | 32,654 |
Total liabilities | 45,688 | 54,839 |
Commitments and contingencies (Note 11) | ||
Stockholders' deficit | ||
Preferred stock, $0.001 par value; 5,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 5,000,000 shares of the preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value; 260,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 29,715.962 and 29,313,667 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 30 | 29 |
Additional paid-in capital | 598,413 | 599,935 |
Accumulated deficit | (601,597) | (599,977) |
Accumulated other comprehensive loss | (866) | (866) |
Total stockholders' deficit | (4,020) | (879) |
Total liabilities and stockholders' deficit | $ 41,668 | $ 53,960 |